Oncology Company Demonstrates Long-Term Stability and Viability From Biobank Study

The integration of artificial intelligence and biobanking has emerged as a formidable force, enabling researchers to harness vast volumes of data in the quest to develop novel therapies. At the forefront of this revolution is Predictive Oncology Inc. (NASDAQ: POAI), a company that has recently announced compelling findings from a study examining the long-term stability and viability of its proprietary biobank of primary tumor specimens. $Predictive Oncology (POAI.US)$